NEVERMINED-AG
12.7.2022 15:02:09 CEST | Business Wire | Press release
Nevermined AG , a Web3 company that provides tools to read, write and own your digital assets, announced their initial investment round of €3 million, co-led by Signature Ventures and Polymorphic Capital. The Nevermined platform consists of modular solutions that easily allow users the ability to create and monetize digital assets and participate in the read-write-own vision of Web3.
The platform offers the foundations for building digital ecosystems with components like Tokenization Engine, Marketplace Creator, Royalties Engine, Decentralized Access Control, DAO Framework and DISC, or Data In-Situ Computation, for Remote Computation.
Nevermined CEO Don Gossen shares, “The best internet is the one that everyone can access and own. And this is what Nevermined allows people to do. When it comes to Data mixed with Web3 our pedigree speaks for itself – our team has been working with cutting-edge tech for over 20 years, first in Big Data, and now in Web3. With these building blocks, we can help you realize your vision. I’d argue we’re the best team in the world that does what we do.”
According to a new report by Grand View Research , the global blockchain technology market size is expected to reach $1,431 billion by 2030. With this market opportunity and its solid, proven technology, Nevermined will leverage this capital raise to:
Be more complete and scalable by advancing its product roadmap: Nevermined will enhance its digital asset development platform that makes Web3 accessible by streamlining the creation, monetization and management of decentralized digital assets. Some key projects include:
- Enterprise: A global energy company used the platform to create a peer-to-peer carbon certificate trading marketplace.
- Creative: Autonomies is using Nevermined to build a music NFT platform and DAO, allowing for fairer value distribution between musicians, labels and collectors.
- Science: In a world first, VitaDAO used Nevermined to tokenize the IP of scientific research, conducted by the Scheibye-Knudsen Lab in Copenhagen.
Be more accessible by accelerating global footprint: To foster company growth and better customer experience, Nevermined will be strengthening its presence in key areas including product, engineering, marketing and community.
Be easier to use by expanding the breadth and depth of the partner ecosystem: Nevermined will establish both technical and creative partnerships that will bolster its mission. Along with deepening partnerships with initiatives such as Autonomies , a music NFT platform allowing artists to become stakeholders.
“We only invest in outstanding teams that build the backbone of the decentralized future,'' said Managing Director Juliane Hahn, Signature. “We see many startups that try to combine Data with Blockchains. Nevermined is the first company that understands the complexities and provides actual solutions at the intersection of Data and Web3. In the future every data-driven company will require the ability to turn their data silos into data ecosystems. Nevermined delivers the full product stack to do just that.”
“We’ve been very impressed with the Nevermined team,” said Vitaly Spassky, founder of Polymorphic Capital. “They have the vision, as well as the tech talent and pedigree to execute. To us digital assets are a crucial building block for the decentralized web. And the Nevermined platform makes it super easy for teams and projects to integrate Web3 tech. We’re very excited to see what people will build with Nevermined.”
Nevermined began as an incubation project within Keyko AG to solve issues around data sharing using tokenization and smart contract gateways. From there it evolved from a data-centric solution to a decentralized digital assets solution with much broader applicability.
About Nevermined
Nevermined is a Web3 company that provides tools to read, write and own your digital assets, founded by CEO Don Gossen, CTO Aitor Argomaniz and CIO Dimitri De Jonghe. They met while creating Ocean Protocol, the world’s first decentralized data marketplace. In 2019, they founded Keyko over a shared belief in the power of digital ecosystems. They helped a variety of organizations develop Web3 ecosystems, worth a combined value of $3 billion. In 2022, they decided to spin out Nevermined as a standalone technology platform.
More info on https://nevermined.io/
About Signature Ventures
Signature Ventures is an early-stage Venture Capital fund investing in Blockchain, Distributed Ledger Technology and Web3 technology. Based in Germany, the fund invests in Pre-Seed to Series A, globally with a focus on Europe. Signature Ventures is managed by Juliane Hahn, Founding Partner, and Dr. Georg Stricker, Tech Partner. They combine an extensive track record of VC investments with deep Blockchain expertise.
About Polymorphic Capital
Polymorphic Capital is a venture capital firm that invests globally in teams creating the future of the internet with decentralized protocols and digital assets. They specialize in infrastructure, finance and gaming.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220712005503/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom